Cargando…
The predictive impact of dual somatostatin receptor/fluorodeoxyglucose (FDG) positron emission tomography (PET) in metastatic gastroenteropancreatic neuroendocrine tumors (GEP-NETs): review of literature and a single institution experience
Treatment with radiolabelled somatostatin analogs, a form of peptide receptor radionuclide therapy (PRRT), has changed the management of patients with advanced gastroenteropancreatic neuroendocrine tumors (GEP-NETs). There is a subgroup of patients who have suboptimal benefit and rapidly progress on...
Autores principales: | , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
AME Publishing Company
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10186532/ https://www.ncbi.nlm.nih.gov/pubmed/37201086 http://dx.doi.org/10.21037/jgo-22-1011 |
_version_ | 1785042579828506624 |
---|---|
author | Mohamed, Amr Asa, Sylvia L. Lee, Zhenghong Tirumani, Sree H. Li, Qiubai Avril, Norbert Bajor, David Mahipal, Amit Chakrabarti, Sakti Selfridge, J. Eva Kardan, Arash |
author_facet | Mohamed, Amr Asa, Sylvia L. Lee, Zhenghong Tirumani, Sree H. Li, Qiubai Avril, Norbert Bajor, David Mahipal, Amit Chakrabarti, Sakti Selfridge, J. Eva Kardan, Arash |
author_sort | Mohamed, Amr |
collection | PubMed |
description | Treatment with radiolabelled somatostatin analogs, a form of peptide receptor radionuclide therapy (PRRT), has changed the management of patients with advanced gastroenteropancreatic neuroendocrine tumors (GEP-NETs). There is a subgroup of patients who have suboptimal benefit and rapidly progress on PRRT, indicating that accurate prognostic and predictive markers are urgently needed. Currently, most of the literature concentrate on the prognostic impact of the dual positron emission tomography (PET) scan with very few information regarding the predictive value. We report a case series and review the literature to summarizes the predictive value of combined somatostatin receptor (SSTR) and fluorodeoxyglucose (FDG) PET in metastatic GEP-NETs. We conducted a review of the literature for data published from 2010 to 2021 in MEDLINE, Embase, the National Institutes of Health trial registry, Cochrane CENTRAL, and published proceedings from major gastrointestinal and neuroendocrine cancer meetings. Our main criteria included all published prospective and retrospective data in which the predictive value of dual PET scans using SSTR and FDG was correlated with PRRT response in patients with metastatic GEP-NETs. We summarized clinical outcomes including progression-free survival (PFS), overall survival (OS), and post-therapy complications associated with PRRT according to FDG avidity. We excluded studies that did not include FDG PET scan, GEP patients, studies with no clear predictive value of the FDG PET scan, and studies that did not report a direct correlation between FDG avidity and primary outcome. Additionally, we summarized our institutional experience in eight patients who progressed during or within the first year of PRRT treatment. Our search identified 1306 articles; most of them showed only the prognostic value of Integrated SSTR/FDG PET imaging biomarker in GEP-NETs. Only three studies (n=75 patients) met our inclusion criteria and retrospectively investigated the predictive value of dual SSTR and FDG imaging in subjects being considered for PRRT. The results confirmed that FDG avidity correlates with advanced NET grades. Lesions that are both SSTR and FDG avid had early disease progression. In one study, at multivariate analysis, FDG PET results were independently predictive of lower PFS for PRRT. In our case series, there were eight patients with metastatic well-differentiated GEP-NETs (grades 2 and 3) who progressed within one year of PRRT. Seven of them had positive FDG PET scan at the time of progression. In conclusion, Dual SSTR/FDG PET imaging has a potential predictive impact for PRRT in GEP-NETs. It permits the capturing of the disease complexity and aggressiveness, which correlates with PRRT response. Therefore, prospective future trials should validate the predictive value of dual SSTRs/FDG PET for better PRRT stratification. |
format | Online Article Text |
id | pubmed-10186532 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2023 |
publisher | AME Publishing Company |
record_format | MEDLINE/PubMed |
spelling | pubmed-101865322023-05-17 The predictive impact of dual somatostatin receptor/fluorodeoxyglucose (FDG) positron emission tomography (PET) in metastatic gastroenteropancreatic neuroendocrine tumors (GEP-NETs): review of literature and a single institution experience Mohamed, Amr Asa, Sylvia L. Lee, Zhenghong Tirumani, Sree H. Li, Qiubai Avril, Norbert Bajor, David Mahipal, Amit Chakrabarti, Sakti Selfridge, J. Eva Kardan, Arash J Gastrointest Oncol Review Article Treatment with radiolabelled somatostatin analogs, a form of peptide receptor radionuclide therapy (PRRT), has changed the management of patients with advanced gastroenteropancreatic neuroendocrine tumors (GEP-NETs). There is a subgroup of patients who have suboptimal benefit and rapidly progress on PRRT, indicating that accurate prognostic and predictive markers are urgently needed. Currently, most of the literature concentrate on the prognostic impact of the dual positron emission tomography (PET) scan with very few information regarding the predictive value. We report a case series and review the literature to summarizes the predictive value of combined somatostatin receptor (SSTR) and fluorodeoxyglucose (FDG) PET in metastatic GEP-NETs. We conducted a review of the literature for data published from 2010 to 2021 in MEDLINE, Embase, the National Institutes of Health trial registry, Cochrane CENTRAL, and published proceedings from major gastrointestinal and neuroendocrine cancer meetings. Our main criteria included all published prospective and retrospective data in which the predictive value of dual PET scans using SSTR and FDG was correlated with PRRT response in patients with metastatic GEP-NETs. We summarized clinical outcomes including progression-free survival (PFS), overall survival (OS), and post-therapy complications associated with PRRT according to FDG avidity. We excluded studies that did not include FDG PET scan, GEP patients, studies with no clear predictive value of the FDG PET scan, and studies that did not report a direct correlation between FDG avidity and primary outcome. Additionally, we summarized our institutional experience in eight patients who progressed during or within the first year of PRRT treatment. Our search identified 1306 articles; most of them showed only the prognostic value of Integrated SSTR/FDG PET imaging biomarker in GEP-NETs. Only three studies (n=75 patients) met our inclusion criteria and retrospectively investigated the predictive value of dual SSTR and FDG imaging in subjects being considered for PRRT. The results confirmed that FDG avidity correlates with advanced NET grades. Lesions that are both SSTR and FDG avid had early disease progression. In one study, at multivariate analysis, FDG PET results were independently predictive of lower PFS for PRRT. In our case series, there were eight patients with metastatic well-differentiated GEP-NETs (grades 2 and 3) who progressed within one year of PRRT. Seven of them had positive FDG PET scan at the time of progression. In conclusion, Dual SSTR/FDG PET imaging has a potential predictive impact for PRRT in GEP-NETs. It permits the capturing of the disease complexity and aggressiveness, which correlates with PRRT response. Therefore, prospective future trials should validate the predictive value of dual SSTRs/FDG PET for better PRRT stratification. AME Publishing Company 2023-03-31 2023-04-29 /pmc/articles/PMC10186532/ /pubmed/37201086 http://dx.doi.org/10.21037/jgo-22-1011 Text en 2023 Journal of Gastrointestinal Oncology. All rights reserved. https://creativecommons.org/licenses/by-nc-nd/4.0/Open Access Statement: This is an Open Access article distributed in accordance with the Creative Commons Attribution-NonCommercial-NoDerivs 4.0 International License (CC BY-NC-ND 4.0), which permits the non-commercial replication and distribution of the article with the strict proviso that no changes or edits are made and the original work is properly cited (including links to both the formal publication through the relevant DOI and the license). See: https://creativecommons.org/licenses/by-nc-nd/4.0 (https://creativecommons.org/licenses/by-nc-nd/4.0/) . |
spellingShingle | Review Article Mohamed, Amr Asa, Sylvia L. Lee, Zhenghong Tirumani, Sree H. Li, Qiubai Avril, Norbert Bajor, David Mahipal, Amit Chakrabarti, Sakti Selfridge, J. Eva Kardan, Arash The predictive impact of dual somatostatin receptor/fluorodeoxyglucose (FDG) positron emission tomography (PET) in metastatic gastroenteropancreatic neuroendocrine tumors (GEP-NETs): review of literature and a single institution experience |
title | The predictive impact of dual somatostatin receptor/fluorodeoxyglucose (FDG) positron emission tomography (PET) in metastatic gastroenteropancreatic neuroendocrine tumors (GEP-NETs): review of literature and a single institution experience |
title_full | The predictive impact of dual somatostatin receptor/fluorodeoxyglucose (FDG) positron emission tomography (PET) in metastatic gastroenteropancreatic neuroendocrine tumors (GEP-NETs): review of literature and a single institution experience |
title_fullStr | The predictive impact of dual somatostatin receptor/fluorodeoxyglucose (FDG) positron emission tomography (PET) in metastatic gastroenteropancreatic neuroendocrine tumors (GEP-NETs): review of literature and a single institution experience |
title_full_unstemmed | The predictive impact of dual somatostatin receptor/fluorodeoxyglucose (FDG) positron emission tomography (PET) in metastatic gastroenteropancreatic neuroendocrine tumors (GEP-NETs): review of literature and a single institution experience |
title_short | The predictive impact of dual somatostatin receptor/fluorodeoxyglucose (FDG) positron emission tomography (PET) in metastatic gastroenteropancreatic neuroendocrine tumors (GEP-NETs): review of literature and a single institution experience |
title_sort | predictive impact of dual somatostatin receptor/fluorodeoxyglucose (fdg) positron emission tomography (pet) in metastatic gastroenteropancreatic neuroendocrine tumors (gep-nets): review of literature and a single institution experience |
topic | Review Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10186532/ https://www.ncbi.nlm.nih.gov/pubmed/37201086 http://dx.doi.org/10.21037/jgo-22-1011 |
work_keys_str_mv | AT mohamedamr thepredictiveimpactofdualsomatostatinreceptorfluorodeoxyglucosefdgpositronemissiontomographypetinmetastaticgastroenteropancreaticneuroendocrinetumorsgepnetsreviewofliteratureandasingleinstitutionexperience AT asasylvial thepredictiveimpactofdualsomatostatinreceptorfluorodeoxyglucosefdgpositronemissiontomographypetinmetastaticgastroenteropancreaticneuroendocrinetumorsgepnetsreviewofliteratureandasingleinstitutionexperience AT leezhenghong thepredictiveimpactofdualsomatostatinreceptorfluorodeoxyglucosefdgpositronemissiontomographypetinmetastaticgastroenteropancreaticneuroendocrinetumorsgepnetsreviewofliteratureandasingleinstitutionexperience AT tirumanisreeh thepredictiveimpactofdualsomatostatinreceptorfluorodeoxyglucosefdgpositronemissiontomographypetinmetastaticgastroenteropancreaticneuroendocrinetumorsgepnetsreviewofliteratureandasingleinstitutionexperience AT liqiubai thepredictiveimpactofdualsomatostatinreceptorfluorodeoxyglucosefdgpositronemissiontomographypetinmetastaticgastroenteropancreaticneuroendocrinetumorsgepnetsreviewofliteratureandasingleinstitutionexperience AT avrilnorbert thepredictiveimpactofdualsomatostatinreceptorfluorodeoxyglucosefdgpositronemissiontomographypetinmetastaticgastroenteropancreaticneuroendocrinetumorsgepnetsreviewofliteratureandasingleinstitutionexperience AT bajordavid thepredictiveimpactofdualsomatostatinreceptorfluorodeoxyglucosefdgpositronemissiontomographypetinmetastaticgastroenteropancreaticneuroendocrinetumorsgepnetsreviewofliteratureandasingleinstitutionexperience AT mahipalamit thepredictiveimpactofdualsomatostatinreceptorfluorodeoxyglucosefdgpositronemissiontomographypetinmetastaticgastroenteropancreaticneuroendocrinetumorsgepnetsreviewofliteratureandasingleinstitutionexperience AT chakrabartisakti thepredictiveimpactofdualsomatostatinreceptorfluorodeoxyglucosefdgpositronemissiontomographypetinmetastaticgastroenteropancreaticneuroendocrinetumorsgepnetsreviewofliteratureandasingleinstitutionexperience AT selfridgejeva thepredictiveimpactofdualsomatostatinreceptorfluorodeoxyglucosefdgpositronemissiontomographypetinmetastaticgastroenteropancreaticneuroendocrinetumorsgepnetsreviewofliteratureandasingleinstitutionexperience AT kardanarash thepredictiveimpactofdualsomatostatinreceptorfluorodeoxyglucosefdgpositronemissiontomographypetinmetastaticgastroenteropancreaticneuroendocrinetumorsgepnetsreviewofliteratureandasingleinstitutionexperience AT mohamedamr predictiveimpactofdualsomatostatinreceptorfluorodeoxyglucosefdgpositronemissiontomographypetinmetastaticgastroenteropancreaticneuroendocrinetumorsgepnetsreviewofliteratureandasingleinstitutionexperience AT asasylvial predictiveimpactofdualsomatostatinreceptorfluorodeoxyglucosefdgpositronemissiontomographypetinmetastaticgastroenteropancreaticneuroendocrinetumorsgepnetsreviewofliteratureandasingleinstitutionexperience AT leezhenghong predictiveimpactofdualsomatostatinreceptorfluorodeoxyglucosefdgpositronemissiontomographypetinmetastaticgastroenteropancreaticneuroendocrinetumorsgepnetsreviewofliteratureandasingleinstitutionexperience AT tirumanisreeh predictiveimpactofdualsomatostatinreceptorfluorodeoxyglucosefdgpositronemissiontomographypetinmetastaticgastroenteropancreaticneuroendocrinetumorsgepnetsreviewofliteratureandasingleinstitutionexperience AT liqiubai predictiveimpactofdualsomatostatinreceptorfluorodeoxyglucosefdgpositronemissiontomographypetinmetastaticgastroenteropancreaticneuroendocrinetumorsgepnetsreviewofliteratureandasingleinstitutionexperience AT avrilnorbert predictiveimpactofdualsomatostatinreceptorfluorodeoxyglucosefdgpositronemissiontomographypetinmetastaticgastroenteropancreaticneuroendocrinetumorsgepnetsreviewofliteratureandasingleinstitutionexperience AT bajordavid predictiveimpactofdualsomatostatinreceptorfluorodeoxyglucosefdgpositronemissiontomographypetinmetastaticgastroenteropancreaticneuroendocrinetumorsgepnetsreviewofliteratureandasingleinstitutionexperience AT mahipalamit predictiveimpactofdualsomatostatinreceptorfluorodeoxyglucosefdgpositronemissiontomographypetinmetastaticgastroenteropancreaticneuroendocrinetumorsgepnetsreviewofliteratureandasingleinstitutionexperience AT chakrabartisakti predictiveimpactofdualsomatostatinreceptorfluorodeoxyglucosefdgpositronemissiontomographypetinmetastaticgastroenteropancreaticneuroendocrinetumorsgepnetsreviewofliteratureandasingleinstitutionexperience AT selfridgejeva predictiveimpactofdualsomatostatinreceptorfluorodeoxyglucosefdgpositronemissiontomographypetinmetastaticgastroenteropancreaticneuroendocrinetumorsgepnetsreviewofliteratureandasingleinstitutionexperience AT kardanarash predictiveimpactofdualsomatostatinreceptorfluorodeoxyglucosefdgpositronemissiontomographypetinmetastaticgastroenteropancreaticneuroendocrinetumorsgepnetsreviewofliteratureandasingleinstitutionexperience |